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While there is general agreement on the necessity tomeasure glomerular filtration rate (GFR) in many clinical situations, there is
less agreement on the bestmethod to achieve this purpose. As the gold standardmethod for GFR determination, urinary (or renal)
clearance of inulin, fades into the background due to inconvenience and high cost, a diversity of filtration markers and protocols
compete to replace it. In this review, we suggest that iohexol, a non-ionic contrast agent, is most suited to replace inulin as the
marker of choice for GFR determination. Iohexol comes very close to fulfilling all requirements for an ideal GFRmarker in terms of
low extra-renal excretion, low protein binding and in being neither secreted nor reabsorbed by the kidney. In addition, iohexol is
virtually non-toxic and carries a low cost. As iohexol is stable in plasma, administration and sample analysis can be separated in
both space and time, allowing access to GFR determination across different settings. An external proficiency programme operated
by Equalis AB, Sweden, exists for iohexol, facilitating interlaboratory comparison of results. Plasma clearance measurement is
the protocol of choice as it combines a reliable GFR determination with convenience for the patient. Single-sample protocols
dominate, butmultiple-sample protocolsmaybemore accurate in specific situations. In lowGFRs one ormore late samples should
be included to improve accuracy. In patients with large oedema or ascites, urinary clearance protocols should be employed. In
conclusion, plasma clearance of iohexol may well be the best candidate for a common GFR determination method.
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Introduction
Since Homer W. Smith published in 1951 his famous textbook
‘The Kidney: Structure and Function in Health and Disease’,
glomerular filtration rate (GFR) has been considered as one of
the best physiologic measures of kidney function [1]. The histor-
ical gold standard for GFR measurement, which is urinary clear-
ance of inulin, is however difficult to perform in practice. Indeed,
these pioneers of nephrology performed repeated urine collec-
tion every 10 or 15 min with a urinary catheter, a constant infu-
sion of inulin and arterial samples [1, 2]. Several alternatives
such as isotopic (125I-iothalamate, 51Cr-EDTA or 99Tc-DTPA) or
non-isotopic (iohexol or iothalamate) ‘cold’ markers have thus
been proposed to measure GFR [3]. Importantly, the term ‘alter-
native’ also implies that another methodology than urinary
clearance can be used, i.e. plasma clearance [4–6].
Estimated GFR by equations based on creatinine and/or cysta-
tin are less accurate than measured GFR. Although equations
for estimating GFR are useful, especially outside nephrology,
the precision of the equations can be relatively poor in specific
clinical situations (see Part 2 of the article) [7–9]. Also, both
creatinine and cystatin C are influenced by non-GFR factors
[10–12]. This has been demonstrated in several and diverse clin-
ical populations, i.e. diabetes mellitus, chronic kidney disease
(CKD), renal and non-renal transplantation, patients with cirrho-
sis, heart failure and also in healthy subjects [13–18]. Thus, in
many clinical contexts a measured GFR is required.
In Part 1 of this review, wewill focus on iohexol plasma clear-
ance, the most popular method used to measure GFR in Europe.
We will review general properties, safety aspects, analytical
considerations, agreement with other procedures and current
available procedures of iohexol plasma clearance. In Part 2, we
focus on the role of iohexol plasma clearance both in clinical
practice and research.
Iohexol: general properties and safety
Iohexol is a non-ionic contrast medium, a principle developed
by the Swedish radiologist Torsten Almén [19, 20]. It is mainly
used for computed tomography (CT), catheter-based angiog-
raphy and interventions. The first description of iohexol in
humans was published in 1980 [21]. Increasing doses of iohexol
(125–500 mg I/kg) were injected into 20 healthy subjects. In this
seminal study, it was shown that the substance was safe and
fully excreted by the kidneys. In 10 subjects, it was additionally
shown that iohexol did not affect GFR measured by 51Cr-EDTA.
The authors mentioned that urinary clearance of iohexol was
higher than urinary clearance of 51Cr-EDTA, but no additional
details were given [21]. In 1983, data from this first study were
re-analysed [22]. Iohexol total clearance was identical to 51Cr-
EDTA, whereas urinary clearance of iohexol was slightly higher.
Finally, they showed that iohexol was distributed within the
extracellular volume [22]. This iohexol distribution pattern
applies also to patients with CKD and obese subjects [22–26].
Importantly for a GFR marker, other studies demonstrated that
iohexol had no effect on the GFR level per se [21, 27].
Themolecular weight of iohexol is 821 Da [22, 28]. The propor-
tion of iohexol bound to protein appears to be very low. The first
study described a binding to protein of only 1.5% [29], which was
also confirmed byothers [26, 30, 31], although one recent publica-
tion challenged these findings [32]. Regarding its molecular
weight and the absence of binding to proteins, there is little
doubt that this marker is freely filtrated through the glomerulus.
The question of the extra-renal clearance of a marker is im-
portant. Briefly, this question can be studied by two different
methodologies: eithermeasuring the plasmaclearance in aneph-
ric patients (or in patients with very low residual function) or
measuring plasma and urinary clearances, the difference be-
tween both being the extra-renal clearance. Extra-renal clearance
of iohexol is low with both methodologies. Studying anephric
patients, extra-renal clearance of iohexol was between 2 and
3 mL/min/1.73 m2 [24, 33–35]. Studying the difference between
plasma and urinary clearances in healthy subjects, the extra-
renal clearance of iohexol was between 0 and 6 mL/min/1.73 m2
[22, 26, 30, 36] or 5% [25]. These results must be compared
with extra-renal clearance of other markers such as iothalamate
and 51Cr-EDTA,which has been found to be between 4 and 10 mL/
min/1.73 m2 for iothalamate [26, 37–39] and around 2–4 mL/min/
1.73 m2 for 51Cr-EDTA [40, 41].
To be considered a referencemarker formeasuring GFR, there
should not be any tubular secretion or absorption. Iohexol differs
from iothalamate in being non-ionic, and active secretion or
absorption of iohexol has to our knowledge not been demon-
strated. In contrast, a concentration gradient dependent tubular
transport of iothalamate and other ionic contrast media is well
documented in several species, including human [42, 43].
The safety of iohexol has been extensively studied [44, 45] and
is confirmed by the large number of iohexol measurements


















performed in countries, e.g. Sweden (in Skåne county) (∼1500 GFR
measurements/year) [46, 47] and Italy (25 000 iohexol clearances
since 1995 at the Clinical Research Center of Mario Negri Institute
in Bergamo) (F.G., personal data). No severe adverse event, and
particularly no anaphylactic reaction, occurred. This safety pro-
file is, at least in part, explained by the current lowdose of iohexol
injected (5 or 10 mL versus 80–180 mL for CT scan and 130–
300 mL for coronary interventions) and by the exclusion of
patientswith known contrastmedium reactions. Even in patients
with minimal renal function, iohexol doses of 10 mL (300 mg I/
mL) have not been shown to be nephrotoxic by measuring
serum creatinine but also urinary N-acetyl-beta--glucosamini-
dase and α1-microglobulin, at 1 and 4 days after injection [48].
Altogether, the co-authors of this review article have performed
around 10 000 iohexol GFR measurements over the last 2 years.
Anaphylactic shock never occurred.
Iohexol: analytical and other metrics
considerations
Analytical considerations
Iohexol can be measured using different methods. High
performance liquid chromatography with ultraviolet detection
(HPLC-UV), X-ray fluorescence (XRF) and liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) are certainly the
most validated methods. There are other assays, e.g. capillary
electrophoresis, but such methods have been poorly validated,
and nowadays are seldom used [49, 50]. HPLC-UV is clearly the
most commonly used method in Europe and was historically
the first method described [21] to quantify iohexol [30]. Measure-
ment of iohexol by HPLC-UV is sensitive, specific and reprodu-
cible, enabling the use of minute doses of iohexol, as low
plasma concentrations can be accurately quantified [26, 30, 45,
51–59]. The high sensitivity also allowed the development of
finger-prick samples (capillary sampling). However, this capillary
technique needs to be developed further, as the precision of
this method cannot yet be considered sufficient [60–65]. Meas-
urement of iohexol by XRF has been well described [45, 66–72]
but requires specific instrumentation. Few studies have com-
pared these two methods for GFR measurement purposes [69],
yet these data indicate that the performance of XRF is inferior
to HPLC-UV due to its lower sensitivity [69, 73]. Measurement of
iohexol by LC-MS/MS has been more recently described by
several authors [32, 74–79]. LC-MS/MS is theoretically a more
sensitive and specific method but is more complex and costly
compared with HPLC-UV.
A fundamental question is whether differences in iohexol
measurement methodology will affect GFR results, as has been
shown for other markers like inulin or iothalamate [80, 81].
Recent data suggest a high concordance between iohexol concen-
trations and plasma clearances measured by HPLC-UV or LC-MS/
MS in 102 CKD and healthy subjects, but a systematic correction
factor of 10% must be applied [82]. Other authors performed an
inter-laboratory comparison of iohexol measurement. In 20
paediatric patients, they compared iohexol concentrations
(range 15–700 µg/mL) measured by LC-MS/MS in the USA with
those determined on the same samples by HPLC-UV by a
European reference laboratory in Italy. The concordance between
the two methods was very high both for iohexol concentrations
and GFR results (difference of <10% between the two laboratories,
except for one patient) [83]. Further research is still required
regarding the effect of the measurement method (HPLC or LC-
MS/MS) on iohexol (or iothalamate) clearance results.
Two very important analytical points should be highlighted
when discussing GFR measurement. Firstly, iohexol is perfectly
stable at room temperature, −20°C and −80°C [32, 84]. Iohexol
clearance investigations can therefore be performed in virtually
all medical settings. Samples can be measured at a tertiary care
hospital and then shipped to a central laboratory. No shipment
in dry ice is needed. The high stability of iohexol is a major
advantage in comparison with isotopic methods that can be
performed only in nuclearmedicine units and for which samples
are difficult to store.
Secondly, an external quality assurance programme does
exist, provided by Equalis AB, Uppsala, Sweden. Two serum or
plasma samples with added iohexol are distributed to partici-
pants four times per year. Additional data (patient gender, height
and weight for body surface calculation, administered dose of
iohexol and timing of samples) are provided to enable pro-
gramme participants to calculate iohexol clearance using a
one- or two-sample calculation (or both). This proficiency pro-
gramme includes both HPLC-UV (the majority) and LC-MS/MS
measurements. Each laboratory can compare its own results to
that of other participating laboratories. In 2015, 35 laboratories
participated in this programme. Agreement between overall
means and spiked concentrations is high. Between-laboratory
reproducibility for each survey is ∼5% [coefficient of variation
(CV)]. Analysis of variance calculated from repeated distribution
of the same pools over a 3-year period yields a within-laboratory
reproducibility of 5%, a between-laboratory reproducibility of
3–4% and a total variation of 5–7%. The different methods of
iohexol analysis perform equally well. To the best of our knowl-
edge, such an external quality programme does not exist for
other GFR markers wherefore less knowledge is available about
their inter-laboratory variation [56].
Intra-individual variation
The biological variation of any physiological quantity should be
considered in the interpretation of biological results. The bio-
logical CV, represents the ‘normal’ variation of a parameter that
can be observed in the same individual. GFR is influenced by
several physiological parameters such as diet, activity or circa-
dian variations [71, 85–87]. In the case of measured GFR, intra-
individual variation includes both biological variation and the
errors due to the measurement of GFR itself. Variation is thus
dependent on both the markers and measurements protocols
[88]. Ideally, the GFR measurement should be performed using a
standardized procedure, e.g. measurement in a fasting state, in
the same environment and at the same time of day, because all
these parameters are prone to increase intra-individual variation.
Intra-individual variation can also differ according to the popula-
tion tested. For example, intra-individual variation may be higher
in CKD patients than in a healthy population [89], even if this is
not found by all authors [6]. Literature gives an intra-individual
variation of measured GFR (independently of the marker consid-
ered) of 4.2 to 10% [6, 23, 30, 36, 71–73, 86, 88–99]. This means that
in the same given individual, GFR must increase or decrease by at
least 5–15% (depending on the intra-individual CV of the method
used) to be considered clinically relevant. CV of 10% is frequently
considered and should be kept in mind when analysing studies
comparing different GFRmeasurementmethods, or estimated ver-
susmeasuredGFR. In such studies, accuracywithin 10 or 30% is fre-
quently used.Accuracywithin 10% is the percentage of resultswith
onemethod that arewithin ±10% of the results of anothermethod,
and can, with respect to intra-individual variation of GFR, be con-
sidered as an excellent agreement between the methods.


















In Table 1, we summarize estimates of intra-individual vari-
ation published by co-authors of the current article when GFR
is measured with iohexol.
Iohexol: studies comparing iohexol with inulin
clearance
To the best of our knowledge, only two studies have compared
urinary clearances of iohexol and inulin [100, 101] (Table 2).
Both showed excellent correlation between the two methods,
but the statistical tools used in the original publications were
limited and re-analysed data demonstrated less impressive con-
cordance [3]. On the other hand, several studies have compared
iohexol plasma clearances with urinary inulin clearance [52,
102–106]. In general, these studies showed a good correlation
between themethods. Results are less accurate in the study pub-
lished by Erley et al., but the patients included were hospitalized
in an intensive care unit [104]. The value of plasma clearance
(whichever marker) in this setting is probably questionable
because the extracellular volume, and consequently the volume
of distribution of the marker, is quite variable from patient to
patient and within the same patient at different points due to
changes in fluid infusions and in biological fluid loss or seques-
tration in different compartments [104, 107]. Another study did
not describe the slope-intercept method used [102]. The studies
published by Gaspari et al. in adults [52] and Berg et al. in children
[105] are more relevant from a methodological point of view (see
Table 2 for details). They showed low bias and relatively good
precision between the two methods. Both studies included a
large number of samples including a late sample (600 and
1440 min), the last point being of importance as it will be de-
scribed further in the text [52, 105].
In a recent review article [3], authors pooled data from seven
available studies comparing iohexol (both plasma or urinary
clearance) with GFR measured by inulin and calculated median
bias and accuracy within 30 and 10%. For iohexol urinary clear-
ance studies, the mean (± standard deviation) GFR, measured
by inulin, was 81 ± 38 mL/min/1.73 m2. Median bias (correspond-
ing to the median difference between iohexol and inulin) was
−7% [95% confidence interval (CI): −10 to 0]. Pooled accuracy
within 30% was 100% (CI not reported) and accuracy within 10%
was 53% (95% CI: 41–70). For plasma iohexol clearance studies,
the mean GFR measured by inulin was 66 ± 40 mL/min/1.73 m2.
Median bias for iohexol was +3% (95% CI: 0–6). Pooled accuracy
within 30% was 86% (95% CI: 81–91); accuracy within 10%
was 50% (95% CI: 43–58). We agree with the conclusions of the
authors of this analysis: urinary clearance of iohexol is sufficient-
ly accurate to reflect inulin clearance but the evidence is limited
(47measurements in 47 participants); plasma clearance of iohex-
ol is also sufficiently accurate with moderately strong evidence
(172 measurements in 172 participants) [3].
Iohexol: studies comparing iohexol with other
reference markers
Wewill focus on studieswith themost appropriatemethodology,
i.e. studies with low injected doses (usually no more than 5 or
10 cm3 of iohexol 300 or 240 mg I/mL) but also with the same
procedure used for any markers (Table 3). Indeed, as will be
discussed in the next paragraph, different procedures (urinary
versus plasma clearance or different sampling times) potentially
lead to differences in GFR results, which makes it impossible to
know whether these differences are due to the marker itself or
to the methodology. Finally, we emphasized results from studies
that included appropriate statistical tools, such as Bland and
Altman or accuracy analyses.
51Cr-EDTA clearance is one of the most accurate methods to
measure GFR [3, 116, 117]. It is thus not surprising that several
authors have studied the concordance between both 51Cr-EDTA
clearance and iohexol clearance [22, 30, 58, 68, 69, 72, 84, 92, 93,
109, 113–115]. All relevant studies compared plasma clearances
of both markers and have found excellent agreement [30, 69,
72, 92, 93, 109, 115]. Among these studies, five authors provided
Bland-Altman analyses, displaying little bias (between 0 and
4 mL/min) and excellent precision (95% of the results between 8
and 16 mL/min/1.73 m2) [58, 69, 72, 93, 115]. Based on these
results, one can conclude that plasma clearance of iohexol is
concordant with plasma clearance of 51Cr-EDTA.
Only a few studies compared 99Tc-DTPAwith iohexol and the
majority have questionablemethodologies [66, 68, 70, 102, 111]. A
study in 21 diabetic patients showed good correlation, acceptable
bias (4 mL/min) and precision for plasma clearance of iohexol
and 99Tc-DTPA [70].
Studies comparing iohexol and iothalamate clearances are
of importance as iothalamate, an ionic contrast medium, is the
most frequently used GFR marker in the USA and the only
‘cold’ alternative method to iohexol for measuring GFR. At least
five studies have compared the two markers [24, 26, 32, 82, 108].
Two analyses, performed in healthy people, showed a constant
bias in plasma clearances, with iothalamate clearances being
systematically higher than iohexol clearances [26, 108]. A third
one included patients with severe CKD but results were unreli-
able because statistical analyses were not adequate [24]. In a
recent study, the authors compared urinary clearances of iohexol
and iothalamate in 150 kidney transplant recipients. Contrary to
the majority of other studies, iohexol was measured by LC-MS/
MS. The authors found iothalamate urinary clearance to be
systematically higher (+15%, constant bias thorough the GFR
range) than iohexol urinary clearance [32]. Finally, another recent
study compared plasma clearance of iohexol and iothalamate
in 102 patients with a wide range of GFR. The authors found
a good concordance between iothalamate and iohexol plasma
clearancemeasured byHPLC,whereas iothalamate systematically
Table 1. Examples of GFR variability with different iohexol procedures
Author
Reference Sample Protocol Population
GFR variability
(CV)
Krutzen [30] 9 PC: samples at 120 and 240 min + BM correction Healthy 11.4%
Delanaye [73] 12 PC: samples at 120 and 240 min + BM correction Healthy 4.5%
Eriksen [99] 88 PC: single-sample + Jacobsson correction General population 4.2%
Gaspari [6] 24 PC: samples at 120, 150, 180, 210 and 240 if eGFR >40 mL/minand at 120, 180,
240, 300, 450 and 600 min if eGFR <40 mL/min
+ BM correction
Healthy and CKD 5.6%
eGFR, estimated glomerular filtration rate; CV, coefficient of variation; CKD, chronic kidney disease; PC, plasma clearance; BM, Brochner-Mortensen [116].
























1.73 m2) Methodology Statistics Results Comments















Io = 0.85In + 8.79
1.09 ± 0.06
High dose of iohexol
Ratio at 1.36 for 6 patients with
GFR <20 mL/min
BA (Io− In) calculated: 4.3 ± 27 mL/
min




30 Post-surgery 10–125 In
UC
Io (XRF)
UC (three collections of 30 min)







Io = 0.998In − 2.31
PC
0.983
Io = 0.947In + 4.92
1.102 ± 0.286
One patient with oedema
High dose of iohexol (10–50 cm3)
Lindblad
[103]
46 Children 25–150 In
UC (n = 54)
PC (n = 20)
Io (XRF)
PC: samples at 60, 120 and 180 min
Correlation 0.766 Different doses injected
Correction for the first curve NA




41 CKD 6–160 In
UC
Iohexol (HPLC)
PC: samples at 5, 10, 20, 30, 45, 60, 90, 120, 180, 240, 300, 450
and 600 min
AUC











Io = 0.994In + 1.809
4 had moderate oedema
Regression not different from
identity line
Results in 20 patients with GFR <40
(BM): r = 0.908
Io = 0.852In + 4.789
Erley [104] 31 Intensive care unit 10–130 In
UC
Io (XRF)
PC: samples at 150, 195, 240 and 360 min (360 if estimated





Io = 0.971In + 7.65
=8.67 ± 7.21
Authors do not mention how PC
was calculated








Infusion, plasma samples at 270, 330, 390 and 420 min and
urinary collection between 300 and 360 and 360 and
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overestimated (by 10%) iohexol results measured by mass spec-
trometry [82].
Generally, these results head towards the same direction: GFR
measured with iothalamate yields higher results than iohexol.
According to Seegmiller et al., there are different theoretical ex-
planations for this discrepancy: iohexol tubular reabsorption,
iothalamate tubular secretion or iohexol binding protein [32].
However, among these hypotheses, only the tubular secretion
of iothalamate is well described in the literature [42, 43]. Our in-
terpretation is that iohexol is a better marker of GFR than iotha-
lamate because tubular secretion of iothalamate leads to GFR
overestimation.
Plasma clearance: between physiology, safety
and pragmatism
Avariety ofmethodologies or procedures can be used tomeasure
GFR with iohexol; most of these are not iohexol-specific and can
be applied to othermarkers like 51Cr-EDTAor iothalamate. Differ-
ent procedures have different degrees of complexity and preci-
sion and can therefore lead to slightly different results.
Urinary versus plasma clearance
Iohexol is almost always injected as a bolus either for urinary or
plasma clearance determinations, whereas constant infusion of
iohexol [30, 36, 101] for urinary clearance measurement has sel-
dom been used (Supplementary data, Table S1). Several publica-
tions have compared iohexol urinary and plasma clearances [28,
33, 36, 48, 77, 100, 101, 118]. Among these studies, the results pub-
lished by Stolz et al. should be highlighted because 342 subjects
were included and adequate statistical tools were applied [77].
Most studies find plasma clearances to be higher than urinary
clearances. Two important points must be emphasized.
First, the timing of the last plasma sample inmultiple-sample
methods is fundamental: concordance between urinary and
plasma clearance improves if the last iohexol measurement
was performed late. This is particularly true in the very low
GFR ranges [77, 118, 119]. Therefore, in all CKD patients (i.e. GFR
<45 mL/min), it should be recommended to extend plasma sam-
pling until 5, 6 or even 8 h after injection. Gaspari et al. studied
GFR in a cohort of patients with CKD (GFR <40 mL/min) and plas-
ma samples taken hourly up to 8 h. GFR was calculated by using
all available samples or by using only those collected up to 5 h
after iohexol injection. The authors showed that GFRwas overes-
timated on average by 7% in comparison with GFR measured up
to 8 h (F.G., personal data). Thus, timing of the last sample is cru-
cial. In more advanced CKD (stage 5), an additional sample after
24 h has been recommended by some groups [48, 77]. This late
sample is however not always easy to implement in clinical prac-
tice. This approach has been questioned by others arguing for the
circadian variation of GFR [85, 87, 120]. Moreover, a rather long
interval between the two last samples could potentially make
the mathematical weight of the 24 h sample exaggerated in the
final GFR calculation.
Second, urinary clearance is the only option in specific clinical
situations where marker distribution takes several days, i.e. in
patients with severe oedema or ascites.
Both of these two last requirements apply to all plasma clear-
ance procedures and to all GFR markers [4, 107, 121–125].
We recommend a pragmatic approach when choosing the
GFR measurement method: while urinary clearance may be the
most physiologic and accurate method to measure the filtering





























































































































































































































































































































































































































































































Table 3. Studies comparing iohexol clearance with other GFR markers (except inulin)
Reference Sample size Population
GFR range
(mL/min/
1.73 m2) Methodology Statistics Results Comments
Olsson [22] 10 Healthy NA Cr
UC
Collection between 120 and 240 and











High doses of iohexol
Krutzen [30] 42 Healthy and CKD 24–207 Cr







Io = 0.99Cr − 1.92
O’Reilly [84] 54 (100 cm3 Io)
33 (50 cm3 Io)
NA 30–130 Cr
PC: samples at 60, 120, 180 and 240 min
Io (XRF)
PC: samples at 180 and 240 min
Correlation 100 cm3: 0.9
50 cm3: 0.85
High doses of iohexol
Correction for the first curve
NA
Bäck [108] 18 Healthy NA It (HPLC)




Mean GFR by It 40%
higher than mean GFR
by Io
Different doses are injected (2
to 20 cm3)
Bäck [26] 7 Healthy women 100–140 It (HPLC)
PC: samples at 2, 5, then every 5 min for






O’Reilly [66] 33 measurements
in 12 subjects
NA 20–100 Dt
PC: samples at 90, 135, 180 and 240 min
Io (XRF)
PC: samples at 180 and 240 min
Correlation 0.95 High doses of iohexol
Correction for the first curve
NA







UC: 3 collections of 20 min
Io (XRF)





Io = 0.89Dt + 6.5
1.08 ± 0.06
High dose of iohexol
BA calculated:−0.7 ± 14.8
Correction for the first curve
NA
Effersöe [68] 15 Patients for
urography
22–110 Cr and Dt










Io = 0.97Dt − 11
0.96
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Eriksson
[109]
98 Diabetics 30–150 Cr
PC: samples at 220 min





Cr = 1Io− 0.8
0.965
Stake [111] 11 Children with
severe CKD
8–30 Dt
PC: samples at 5, 15, 120, 150, 180 and
210 min
+ Rootwelt correction [112]
Io (XRF)
PC: 6 samples between 180 and 1440 min
+ BM correction
BA Dt− Io Io 6 samples:
13 ± 2 mL/min
Dt:
17 ± 2 mL/min
High doses of iohexol
Dt significantly higher than
Io 6 samples but no
difference if Io sampled
at the same time as Dt
Lundqvist
[113]
31 Plegic patients 70–130 Cr




BA Cr− Io Day 1: +2.1 ± 10.2
Day 2: +0.9 ± 5.9
High doses of iohexol
Nossen [24] 8 Severe CKD 5–9 It
UC: 11 collections between 0 and 7200 min
PC: samples at 30, 60, 120, 180, 360, 540,


















High doses of iohexol
Rydström
[92]
122 Healthy and CKD 4–139 Cr
PC: samples at 180, 200, 220, 240 and














PC: samples at 180, 210, 240, 270 min
+ BM correction
Io (XRF)






Io = 0.892Cr + 6.278
2 ± 9.2
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Table 3. Continued
Reference Sample size Population
GFR range
(mL/min/






PC: samples at 150, 195 and 240 min
+ BM correction










Io = 1.05Cr − 4.43
0.96
−0.16 ± 6.17
Slope not different from 1
and intercept not
different from 0
Pucci [72] 32 Diabetics 13–151 Cr
PC: samples at 5, 10, 15, 30, 60, 90, 120, 150,
180, 210, 240, 270, 300, 360, 420 and 1440
(360 and 420 if creatinine >2 mg/dL, 1440












21 Diabetics 50–145 Dt
PC: samples at 120, 165 and 210 min
+ BM correction
Io (XRF)






Io = 0.9938Dt + 4.916
0.97
4.3 ± 7.7
Pucci [93] 41 Diabetics 29–150 Cr
PC: samples at 5, 10, 15, 30, 60, 90, 120, 150,
180, 210, 240, 270, 300, 360, 420 and 1440
(360 and 420 if creatinine >2 mg/dL, 1440



























BA Cr− Io 4 ± 7.9
Slack [58] 10 Cirrhotic 45–100 Cr
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Seegmiller
[32]
150 Healthy and CKD 5–150 It







Io = 0.85It + 0.44
−15% ± 10%





102 Healthy and CKD 15–130 It
PC: samples at 120, 180, 240 and 300 min
+ BM correction















Io = 0.88It + 7
−2% ± 13%
80%
Io = 0.88It + 1
−11% ± 9%
74%
GFR, glomerular filtration rate; AUC, area under the curve; BA, Bland and Altman (bias ± standard deviation). BA calculated means that BA results have recalculated from data available in the article. BM, Brochner-Mortensen; CKD,
chronic kidney disease; Cr, 51Cr-EDTA; Dt, 99Tc-DTPA; HPLC, high performance liquid chromatography; Io, iohexol; It, iothalamate; NA, not available; PC, plasma clearance; UC, urinary clearance; XRF, X-ray fluorescence. All GFR results
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in the measurement of urinary flows. Plasma clearance methods
represent the best compromise between physiology and feasibil-
ity, both in clinical routine and research [for example: REIN (Ra-
mipril Efficacy In Nephropathy), REIN-2, DEMAND (Developing
Education on Microalbuminuria for Awareness of Renal and Car-
diovascular Risk in Diabetes) and ALADIN (A Long-Acting Som-
atostatin on Disease Progression in Nephropathy due to
Autosomal Dominant Polycystic Kidney Disease) studies] [126–
129]. Monitoring plasma clearance is far less cumbersome and
costly, especially in older adults or diabetic patients with bladder
dysfunction and young children for whom urine collection re-
mains challenging [130, 131]. Once again, these limitations are
common in all GFR markers, including the gold standard inulin.
Bladder catheterization has been used in small studies but this
approach is obviously not feasible in clinical trials or clinical
practice [132].
There may be one potential limitation of urinary clearance
that applies specifically to iohexol, as some authors have actually
hypothesized that measurement of iohexol in urine could be
problematic (matrix effect). This matrix effect remains however
purely speculative and other authors do not have any problem
in quantification of iohexol in urine (F.G., personal data). This
point is thus the subject of debate andwould need further studies
[118].
Plasma clearance: ok but which one?
Because of its physical characteristics (viscosity and density), io-
hexol is particularly suitable for plasma clearancemeasurement.
After a bolus injection, plasma iohexol concentration will de-
crease constantly according to two different exponential curves
(see Figure 1). The first rapid curve (fast component) corresponds
to the volumeof distribution, i.e. the extracellular volume [22–26].
The second curve (slow component) corresponds to the clearance
of the marker by the kidney. There are several different method-
ologies to calculate GFR from the disappearance curves. Themost
precisemethod is tomeasure iohexol in both components, and to
calculate the area under the curve which eventually allows GFR
calculation [which corresponds to the dose of iohexol injected di-
vided by the area under the curve (AUC)]. This method, named
AUC in the current article, implies sampling of several plasma
measurements at different time points. Iohexol should be
sampled at very short intervals at the beginning (at 5, 10, 20, 30,
45, 60, 90 and 120 min after injection [52]), and thereafter every
hour. This methodology is complex and costly, especially with
necessary repeated samples during the first 2 h. For this reason,
authors have proposed a mathematical correction for the first
fast exponential curve. This method is frequently named as the
slope-intercept method. Different mathematical corrections
have been proposed [131, 133, 134, 135]. The impact of these dif-
ferent corrections on GFR results is probably relatively limited.
The correction proposed by Brochner-Mortensen (BM) [116], ini-
tially developed for 51Cr-EDTA, is the most used in Europe:
BM correction= 0.990778 × C2− 0.001218 × C22 (where C2 is the
GFR calculated on the second curve only) [116]. The correction
proposed by Ng et al. both for adults and children [131] has still
been poorly externally validated but has been developed from a
state of the art methodology and deserves further study [118,
131].
The most important limitation of the mathematical correc-
tion of the first curve area is the trend to underestimate high
GFR levels (which could lead to underdiagnosis of renal hyperfil-
tration) [136, 137].
Different protocols have been proposed to calculate the area
under the second curve (the curve that impacts the GFR result).
The number and, even more important, the timing of samples
are fundamental. A simple procedurewould be tomeasure iohex-
ol at two or three different time points. Restricting the GFRmeas-
urement to two pointsmight theoretically expose to a greater risk
of errors (if the first sample is drawn too early or the last sample
not late enough). However, most studies with this protocol show
that this easy-to-use procedure gives accurate and concordant
results with urinary clearances or multiple-samples plasma
clearances [52, 135].When using simplified protocols, it is recom-
mended to perform the first sample not earlier than 2 h after in-
jection. The choice of the timing for the last sample depends on
expected GFR levels [48, 52, 130]. For example, in patients with
normal GFR values, the last measurement can be sampled 4 h
after the injection because later samples would lead to the risk
of complete clearance of iohexol. In CKD patients, the precision
of the GFR calculation will be higher if iohexol is sampled later,
i.e. after 5, 6 or 8 h or even after 24 h in pre-dialysis patients. Sup-
plementary data, Table S2 summarizes studies on the agreement
between different plasma clearance procedures.
Eventually, an even more simplified procedure with only one
sample of iohexol can be used to calculate GFR. Different math-
ematical procedures have been proposed for the calculation of
this single-sample method [92, 110, 114, 138–148]. The equation
proposed by Jacobsson is certainly the most popular in Europe
[110], and, for some investigators, the most precise method
[113, 114].
GFR = (1/(t/V + 0.0016)) × ln (Dose/(V × C1) (in mL/min))
Vmale: 166 ×W + 2490
Vfemale : 95 ×W + 6170 [110]
Ct is the sample concentration (µg/mL) at time t (minute), V is
the apparent volumeof distribution (mL) andW is theweight (kg).
Determination of iohexol by the single-sample method obvi-
ously has great practical advantages. Again, the timing of the sin-
gle-sample is important as it impacts the precision of the GFR
calculation. As previously described, the best results are obtained
when the timing of the sample is adapted to the expected GFR
(based on the subjects estimated GFR), which is however some-
times difficult in very specific patients like hyperfiltrating sub-
jects. An optimal sampling time to minimize the uncertainty in
the estimate of the volume of distribution can be calculated
from a formula derived by Jacobsson [110]. The sample should
be late if GFR is low (300–360 min if GFR between 30 and 60 mL/
min and 600 or 1440 min if GFR is below 30 mL/min) and early
(180 min) if GFR is normal or high [105, 115, 149, 150]. Sinceweight
is part of the equation, the Jacobsson correction might be
Fig. 1. Elimination of iohexol from plasma after a single injection. Following a
single injection, iohexol concentration in plasma falls as a result of both
distribution and elimination. In a semi-logarithmic plot these phases can be
illustrated by two lines, the slopes of which are proportional to the half-life of
each phase.


















questionable in subjects with extreme weights. Indeed, the esti-
mation of extracellular volume is one predominant source of
error with the single-sample method. Also, the single-sample
method requires a very high precision of iohexol determination
in plasma, which is why some authors have suggested that
HPLC-UV be favoured over XRF with this procedure [69, 150]. In
all plasma procedures, potential random analytical, blood draw-
ing or timing errors can sometimes occur, but if there is any error,
potentially outlier points can be easily identified, observing the
declining curve built from multiple-samples results. Outlier
points can thus be discarded (or measurement be repeated).
This sort of internal control does not exist with the single-sample
method. In Supplementary data, Table S3, we have summarized
the available data for single-sample iohexol plasma clearance
[24, 33, 69, 92, 98–101, 103, 105, 109, 114, 115, 149–154]. In general,
the method demonstrated good agreement with either urinary
inulin or plasma 51Cr-EDTA clearance. No study has appropriate-
ly compared the performance of single- and multiple-sample
methodswith inulin urinary clearance as the gold standard refer-
ence. Bird et al. found the performance of the single-sample to be
at least as good as that of themultiple-samplemethod for normal
range GFR when compared to multiple-sample 51Cr-EDTA clear-
ance [115]. Several authors have compared concordance between
single-sample and multiple-sample procedures with iohexol.
Strictly speaking, such studies do not allow the performance of
the two procedures to be tested, as the methods are not inde-
pendent of each other, but the results of concordance between
the two procedures are still of interest. Among these studies,
the publication of Gaspari et al. is certainly the most relevant, in-
cluding 686 patients. These authors found a slight overesti-
mation of 3.2 mL/min/1.73 m2 of the single-sample method for
GFR over 100 mL/min/1.73 m2 when comparing it with the
multiple-sample method, but after logarithmic transformation
the differencewas the same aswhen using the optimal sampling
time for GFR between 40 and 49 mL/min/1.73 m2 [150]. However,
if bias is acceptable, concordance is not always perfect as 75% of
results are concordant, concordance being defined as results
within 5%. Another definition of concordance (within 10%)
would lead to still more acceptable concordance, especially,
once again, if the sample timing is adapted to the expected GFR.
Single-sample plasma clearance could also be used to meas-
ure residual renal function in haemodialysis patients (iohexol is
injected at the end of one dialysis session and a plasma sample is
captured at the start of the next treatment) [35].
Once again, all these considerations about timing and num-
ber of samples are not iohexol-specific, but also apply to other
GFR markers, such as 51Cr-EDTA or iothalamate [117, 142, 143,
155–167].
A pragmatic proposal
The choice of the procedure (urinary or plasma clearance, timing
and number of plasma samples) will depend on human and fi-
nancial resources and specific centre expertise/experience. The
choice of the procedure may depend on the reason (or the con-
text) of why GFR is being measured. The single-sample plasma
clearance technique is probably the more cost-effective proced-
ure for population studies and renal function monitoring in
large cohorts of patients. If feasible, the multiple-sample plasma
clearance method is probably the most effective approach to
monitor intra-patient GFR changes over time in the context of
clinical trials and every-day clinical practice in individual pa-
tients. In Table 4, we make some suggestions for the choice of
procedures according to the context of GFR measurement. This
Table 4. Available procedures to perform iohexol clearance
Methodology Indication in clinical practice Indication in clinical research
Bibliographic examples
where the procedure is
described into details







[36, 77, 125, 170]
Plasma clearance
Multiple samples (first or fast, second or
slow exponential curves and calculation
of area under the curve)
High GFR values
(‘hyperfiltrating’) subjects





Multiple samples only for second and
slow component (2 h after injection, 4




Development of equations to
estimate GFR
Clinical research with GFR as
main endpoint
[126, 172]
Idem+ late sample (8 h or 24 h) Pre-dialysis subjects Research in pre-dialysis subjects [52, 77]
Simplified two or three sample method
(2 samples: first at 2 or 3 h and second at
4 or 5 h) + BM correction
CKD or healthy population Development of equations to
estimate GFR




+ Jacobsson correction [110]
CKD or healthy population Development of equations to
estimate GFR




Suggestions (expert opinion-based) according to the clinical or experimental context.
GFR, glomerular filtration rate; CKD, chronic kidney disease; BM, Brochner-Mortensen correction [116].


















table represents a consensus based on the opinion of the authors
of the current article.
Any of these methods, including the simplest procedure, can
be considered as a good GFR measurement and may be consid-
ered a better reflection of ‘true’ GFR than any equation based
on serum creatinine and/or cystatin C, as these biomarkers are
influenced by non-GFR determinants.
The fact: we need standardization for
measuring GFR
The fact that numerous different markers exist to measure GFR
and that, for each marker, different protocols have been de-
scribed, explains at least in part, why measured GFR has been
questioned [174, 175]. Standardization is a necessary step in pro-
moting GFR measurement. However, standardization is not easy
and can be lengthy. For example, it took years to standardize the
measurement of a simple biological parameter like serum cre-
atinine [176]. For measured GFR, we need standardization at
three different levels. First, the measurement of the markers in
plasmamust be standardized. As alreadymentioned, this is actu-
ally not the case for markers like inulin and iothalamate. Today,
measurement of iohexol by HPLC-UV is the most popular and
probably the best balance between sensitivity-specificity on one
side and accessibility-cost on the other. In the analytical context,
the presence of a proficiency programme (external quality con-
trol) and the stability of iohexol are two key advantages for this
marker. Second, we need standardization regarding the marker
used. We do not question the accuracy of isotopic methods to
measure GFR, but, by nature, these methods are difficult to im-
plement wherefore they remain limited to nuclear medicine
units. Iothalamate clearance overestimates real GFR because of
tubular secretion. Another major issue with iothalamate is its
lack of availability, notably in Europe. Inulin is expensive and
can only be used with urinary protocols. Iohexol plasma clear-
ance seems to be the best choice considering availability, cost,
safety and feasibility. Third, the procedure to measure GFR
should be standardized and we have made some pragmatic pro-
positions earlier in the text (Table 4).
Conclusions
‘Measuring GFR is cumbersome and costly’ is a sentence that has
been written by numerous authors, including some of us, to jus-
tify the use of estimated GFR. It would be counterproductive to
assert that measuring GFR is as simple as measuring creatinine
or cystatin C. However, measured GFR is a reference method.
Therefore, it should be compared to other reference methods in
medicine. Troponin is a key biological parameter for cardiologists
andwe can compare it to serum creatinine for nephrologists. The
sensitivity of troponin to detect myocardial infarction but also to
predict mortality has however not questioned the relevance of
coronary angiography as the reference method. The comparison
might be continued, notably regarding the terms ‘cumbersome’
and ‘costly’. As we described earlier, measuring GFR by iohexol
plasma clearance can be simplified, while keeping a high degree
of precision. Iohexol is available worldwide and provided under
the commercial name Omnipaque® or Accupaque® (240 or
300 mg I/mL) in Europe. Different bottles of iohexol exist and
the price of one bottle of 20 cm3 (to be used for two or four pa-
tients, if 5 or 10 cm3 are injected) is around 10 Euros in Belgium.
Including the price of the HPLCmeasurement, and depending on
the number of samples, the global procedure will cost between
100 and 200 Euros per patient. This cost is comparable to the
cost of other procedures in medicine like any CT scan. The safety
of iohexol protocols is also remarkably superior to that of other
reference methods in medicine such as colonoscopy or coronary
angiography. According to the characteristics of iohexol, we
think that iohexol plasma clearance is clearly the best alternative
to have the same, standardized method for GFR measurement
that would be easy to implement worldwide.
Supplementary data
Supplementary data are available online at http://ckj.oxfordjour-
nals.org.
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